Global Expansion Sword has launched AI powered care operations in the UK and Europe, signaling a clear international expansion strategy. This creates ready made entry points for European hospitals, health systems, and providers seeking to improve access and reduce delays with AI powered care pathways.

Cardiometabolic AI Pulse is an always on AI cardiometabolic solution that expands Sword's offerings into chronic disease management and preventive care. This enables cross sell to health plans and employers seeking scalable, continuous monitoring to lower risk and costs.

Diverse Clientele With over two thousand organizations worldwide across employers, health plans, and governments, Sword demonstrates broad appeal and potential for multichannel sales. The platform spans prevention, treatment, and operations optimization, enabling cross sell opportunities across care pathways.

Proven ROI Sword has helped clients generate over one billion dollars in healthcare savings by avoiding unnecessary procedures such as surgeries, imaging, and ER visits, providing a strong ROI narrative for procurement conversations with risk adjusted budgets.

Trusted Backers Backed by leading investors including Khosla Ventures, General Catalyst, and Founders Fund with a four billion dollar valuation, Sword carries credibility and growth momentum when engaging large hospital systems and payers.